Elutia sells SimpliDerm business to Cellution Biologics for up to $11 million

Reuters2026/08/21 21:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elutia closed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to USD 11 million.
Received USD 8 million in cash at closing, subject to customary inventory adjustments and transaction expenses.
Deal includes up to USD 3 million of contingent milestone payments over the next 18 months.
Divestiture shifts resources toward NXT-41x, with FDA clearance targeted for the first half of 2027.
Proceeds support funding through the first full year of the planned NXT-41x commercial launch in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elutia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-099731), on August 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elutia sells SimpliDerm business to Cellution Biologics for up to $11 million

You may also like

Crypto prices